Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: semi_infinite	6/20/2011 12:45:00 PM
	Read Replies (2) of 3027

How realistic are the concerns below (posted by another poster)? >>>>>>>>>>>>>>>>>>>>> Copaxone Concerns 1) Will the FDA require a clinical trial for m-Copaxone? 2) If MNTA cannot overturn Teva's patents then it will be 2014 or later before we see a generic. 3) Copaxone sales could be damaged goods by 2014 if Biogen's BG12 beats it in September clinicaltrials.gov 4) Tysabri is clearly the most effective drug for MS but sales have been held back by pml. The JC virus test could make Tysabri a 1st line drug for half the MS population that doesn't have the virus. This could take away Copaxone sales.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next